Tyra biosciences reports first quarter 2024 financial results and highlights

- tyra-300 on track in ach and oncology; surf301 ph1 initial results and ach ind submission expected in 2h24 - - cash, cash equivalents, and marketable securities of $382.5 million at q1 2024 - - susan moran, m.d., m.s.c.e. and s.
TYRA Ratings Summary
TYRA Quant Ranking